Korean Journal of Radiology

  • 제16권3호
  • /
  • Pages.449-464
  • /
  • 2015
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

MRI Features of Hepatocellular Carcinoma Related to Biologic Behavior

  • Cho, Eun-Suk (Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Choi, Jin-Young (Department of Radiology, Severance Hospital, Yonsei University College of Medicine)
  • 투고 : 2014.09.03
  • 심사 : 2015.02.23
  • 발행 : 2015.06.01
⟨ 이전 논문 다음 논문 ⟩

초록

Imaging studies including magnetic resonance imaging (MRI) play a crucial role in the diagnosis and staging of hepatocellular carcinoma (HCC). Several recent studies reveal a large number of MRI features related to the prognosis of HCC. In this review, we discuss various MRI features of HCC and their implications for the diagnosis and prognosis as imaging biomarkers. As a whole, the favorable MRI findings of HCC are small size, encapsulation, intralesional fat, high apparent diffusion coefficient (ADC) value, and smooth margins or hyperintensity on the hepatobiliary phase of gadoxetic acid-enhanced MRI. Unfavorable findings include large size, multifocality, low ADC value, non-smooth margins or hypointensity on hepatobiliary phase images. MRI findings are potential imaging biomarkers in patients with HCC.

키워드

참고문헌

  1. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41 https://doi.org/10.1080/13651820410024058
  2. Maida M, Orlando E, Camma C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20:4141-4150 https://doi.org/10.3748/wjg.v20.i15.4141
  3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524 https://doi.org/10.1053/jhep.2002.32089
  4. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235 https://doi.org/10.1007/s00535-005-1566-3
  5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95 https://doi.org/10.1067/mcp.2001.113989
  6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856 https://doi.org/10.1038/nrc1739
  7. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-107 https://doi.org/10.1038/sj.clpt.6100017
  8. Mishra A, Verma M. Cancer biomarkers: are we ready for the prime time? Cancers (Basel) 2010;2:190-208 https://doi.org/10.3390/cancers2010190
  9. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006;26:680-687 https://doi.org/10.1111/j.1478-3231.2006.001285.x
  10. Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, et al. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 2004;30:414-420 https://doi.org/10.1016/j.ejso.2004.01.013
  11. Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am 2010;18:421-450, https://doi.org/10.1016/j.mric.2010.08.002
  12. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-654 https://doi.org/10.1148/radiol.14132361
  13. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-845 https://doi.org/10.1053/he.2000.5628
  14. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278 https://doi.org/10.1002/lt.21999
  15. Giuliante F, Ardito F, Pinna AD, Sarno G, Giulini SM, Ercolani G, et al. Liver resection for hepatocellular carcinoma $\leq$3 cm: results of an Italian multicenter study on 588 patients. J Am Coll Surg 2012;215:244-254 https://doi.org/10.1016/j.jamcollsurg.2012.04.013
  16. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011;17 Suppl 2:S72-S80 https://doi.org/10.1002/lt.22368
  17. Kim KA, Kim MJ, Jeon HM, Kim KS, Choi JS, Ahn SH, et al. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. J Magn Reson Imaging 2012;35:629-634 https://doi.org/10.1002/jmri.22876
  18. Chandarana H, Robinson E, Hajdu CH, Drozhinin L, Babb JS, Taouli B. Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI? AJR Am J Roentgenol 2011;196:1083-1089 https://doi.org/10.2214/AJR.10.4720
  19. Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol 2007;17:2969-2982 https://doi.org/10.1007/s00330-007-0705-z
  20. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30:17-25 https://doi.org/10.1055/s-0030-1247129
  21. Nakashima Y, Nakashima O, Hsia CC, Kojiro M, Tabor E. Vascularization of small hepatocellular carcinomas: correlation with differentiation. Liver 1999;19:12-18 https://doi.org/10.1111/j.1478-3231.1999.tb00003.x
  22. Kondo F, Kondo Y, Nagato Y, Tomizawa M, Wada K. Interstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views. J Gastroenterol Hepatol 1994;9:604-612 https://doi.org/10.1111/j.1440-1746.1994.tb01569.x
  23. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol 2005;19:39-62 https://doi.org/10.1016/j.bpg.2004.10.007
  24. Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S228-S234 https://doi.org/10.1016/S1590-8658(10)60510-5
  25. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-664 https://doi.org/10.1002/hep.22709
  26. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 2011;135:704-715
  27. Choi YS, Rhee H, Choi JY, Chung YE, Park YN, Kim KW, et al. Histological characteristics of small hepatocellular carcinomas showing atypical enhancement patterns on gadoxetic acid-enhanced MR imaging. J Magn Reson Imaging 2013;37:1384-1391 https://doi.org/10.1002/jmri.23940
  28. Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011;261:834-844 https://doi.org/10.1148/radiol.11101840
  29. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50 https://doi.org/10.1148/radiol.14132362
  30. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405-2413 https://doi.org/10.1007/s00330-010-1812-9
  31. Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013;38:290-296 https://doi.org/10.1007/s00261-012-9952-9
  32. Kim MJ, Lee M, Choi JY, Park YN. Imaging features of small hepatocellular carcinomas with microvascular invasion on gadoxetic acid-enhanced MR imaging. Eur J Radiol 2012;81:2507-2512 https://doi.org/10.1016/j.ejrad.2011.11.014
  33. Ooka Y, Kanai F, Okabe S, Ueda T, Shimofusa R, Ogasawara S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging 2013;31:748-754 https://doi.org/10.1016/j.mri.2012.10.028
  34. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002;95:1931-1937 https://doi.org/10.1002/cncr.10892
  35. Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumors of the Digestive System, 4th ed. Lyon: International Agency for Research on Cancer, 2010:205-216
  36. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008;29:1299-1305 https://doi.org/10.1093/carcin/bgn113
  37. Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, et al. Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol 2009;18:25-30 https://doi.org/10.1016/j.suronc.2008.05.009
  38. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003;26:142-147 https://doi.org/10.1016/S1386-6346(03)00007-X
  39. Itoh K, Nishimura K, Togashi K, Fujisawa I, Noma S, Minami S, et al. Hepatocellular carcinoma: MR imaging. Radiology 1987;164:21-25 https://doi.org/10.1148/radiology.164.1.3035606
  40. Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg 2002;137:94-99
  41. Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009;250:435-443 https://doi.org/10.1148/radiol.2501071702
  42. American College of Radiology. Liver Imaging Reporting and Data System version 2013.1. Web site. http://www.acr.org/Quality-Safety/Resources/LIRADS/. Accessed July 19, 2013
  43. Macarini L, Milillo P, Cascavilla A, Scalzo G, Stoppino L, Vinci R, et al. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. Radiol Med 2009;114:1267-1282 https://doi.org/10.1007/s11547-009-0464-9
  44. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992;183:819-825 https://doi.org/10.1148/radiology.183.3.1316622
  45. Grazioli L, Olivetti L, Fugazzola C, Benetti A, Stanga C, Dettori E, et al. The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol 1999;9:62-67 https://doi.org/10.1007/s003300050629
  46. Itai Y, Ohtomo K, Kokubo T, Yamauchi T, Minami M, Yashiro N, et al. CT of hepatic masses: significance of prolonged and delayed enhancement. AJR Am J Roentgenol 1986;146:729-733 https://doi.org/10.2214/ajr.146.4.729
  47. Ng IO, Lai EC, Ng MM, Fan ST. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer 1992;70:45-49 https://doi.org/10.1002/1097-0142(19920701)70:1<45::AID-CNCR2820700108>3.0.CO;2-7
  48. Lee CS, Hwang LY, Beasley RP, Hsu HC, Lee HS, Lin TY. Prognostic significance of histologic findings in resected small hepatocellular carcinoma. Acta Chir Scand 1988;154:199-203
  49. Lai EC, Ng IO, Ng MM, Lok AS, Tam PC, Fan ST, et al. Longterm results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology 1990;11:815-818 https://doi.org/10.1002/hep.1840110516
  50. Lim JH, Choi D, Park CK, Lee WJ, Lim HK. Encapsulated hepatocellular carcinoma: CT-pathologic correlations. Eur Radiol 2006;16:2326-2333 https://doi.org/10.1007/s00330-006-0203-8
  51. Iguchi T, Aishima S, Sanefuji K, Fujita N, Sugimachi K, Gion T, et al. Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol 2009;16:2539-2546 https://doi.org/10.1245/s10434-009-0453-1
  52. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000;33:282-289 https://doi.org/10.1016/S0168-8278(00)80369-4
  53. Yu JS, Chung JJ, Kim JH, Kim KW. Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR Am J Roentgenol 2007;188:1009-1016 https://doi.org/10.2214/AJR.06.0756
  54. Kim TK, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011;259:730-738 https://doi.org/10.1148/radiol.11101549
  55. Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L, et al. Non-invasive diagnosis of hepatocellular carcinoma $\leq$ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 2012;56:1317-1323 https://doi.org/10.1016/j.jhep.2012.01.004
  56. Martin J, Sentis M, Zidan A, Donoso L, Puig J, Falco J, et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995;195:125-130 https://doi.org/10.1148/radiology.195.1.7892452
  57. Mitchell DG, Palazzo J, Hann HW, Rifkin MD, Burk DL Jr, Rubin R. Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. J Comput Assist Tomogr 1991;15:762-769 https://doi.org/10.1097/00004728-199109000-00007
  58. Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J, Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol 2012;199:1018-1025 https://doi.org/10.2214/AJR.12.8632
  59. Ebara M, Fukuda H, Kojima Y, Morimoto N, Yoshikawa M, Sugiura N, et al. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 1999;210:81-88 https://doi.org/10.1148/radiology.210.1.r99ja4181
  60. Shinmura R, Matsui O, Kobayashi S, Terayama N, Sanada J, Ueda K, et al. Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 2005;237:512-519 https://doi.org/10.1148/radiol.2372041389
  61. Enomoto S, Tamai H, Shingaki N, Mori Y, Moribata K, Shiraki T, et al. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int 2011;5:730-737 https://doi.org/10.1007/s12072-010-9245-8
  62. Earls JP, Theise ND, Weinreb JC, DeCorato DR, Krinsky GA, Rofsky NM, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996;201:207-214 https://doi.org/10.1148/radiology.201.1.8816545
  63. Ito K, Fujita T, Shimizu A, Koike S, Sasaki K, Matsunaga N, et al. Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am J Roentgenol 2004;183:699-705 https://doi.org/10.2214/ajr.183.3.1830699
  64. Kelekis NL, Semelka RC, Worawattanakul S, de Lange EE, Ascher SM, Ahn IO, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol 1998;170:1005-1013 https://doi.org/10.2214/ajr.170.4.9530051
  65. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Arai K, Gabata T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173:123-126 https://doi.org/10.1148/radiology.173.1.2550995
  66. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009;27:114-124 https://doi.org/10.1159/000218343
  67. Yu JS, Lee JH, Park MS, Kim KW. Hyperintense nodules on non-enhanced T1-weighted gradient-echo magnetic resonance imaging of cirrhotic liver: fate and clinical implications. J Magn Reson Imaging 2006;24:630-636 https://doi.org/10.1002/jmri.20674
  68. Kojiro M. ‘Nodule-in-nodule’ appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology 2004;47:179-183 https://doi.org/10.1159/000078470
  69. Terada T, Kadoya M, Nakanuma Y, Matsui O. Ironaccumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer 1990;65:1994-2000 https://doi.org/10.1002/1097-0142(19900501)65:9<1994::AID-CNCR2820650919>3.0.CO;2-B
  70. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-142 https://doi.org/10.1055/s-2005-871193
  71. Winter TC 3rd, Takayasu K, Muramatsu Y, Furukawa H, Wakao F, Koga H, et al. Early advanced hepatocellular carcinoma: evaluation of CT and MR appearance with pathologic correlation. Radiology 1994;192:379-387 https://doi.org/10.1148/radiology.192.2.8029401
  72. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009;44 Suppl 19:112-118 https://doi.org/10.1007/s00535-008-2274-6
  73. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008;28:747-769 https://doi.org/10.1148/rg.283055108
  74. Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Matteucci T, Hann HW. Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology 1995;195:753-756 https://doi.org/10.1148/radiology.195.3.7754006
  75. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, et al. Detection of corona enhancement of hypervascular hepatocellular carcinoma by C-arm dual-phase cone-beam CT during hepatic arteriography. Cardiovasc Intervent Radiol 2011;34:81-86 https://doi.org/10.1007/s00270-010-9835-9
  76. Kim H, Park MS, Choi JY, Park YN, Kim MJ, Kim KS, et al. Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI? Eur Radiol 2009;19:1744-1751 https://doi.org/10.1007/s00330-009-1331-8
  77. Kanematsu M, Kondo H, Goshima S, Tsuge Y, Watanabe H. Magnetic resonance imaging of hepatocellular carcinoma. Oncology 2008;75 Suppl 1:65-71 https://doi.org/10.1159/000173426
  78. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology 2009;252:605-614 https://doi.org/10.1148/radiol.2522081414
  79. Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987;60:810-819 https://doi.org/10.1002/1097-0142(19870815)60:4<810::AID-CNCR2820600417>3.0.CO;2-1
  80. Hui AM, Takayama T, Sano K, Kubota K, Akahane M, Ohtomo K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000;33:975-979 https://doi.org/10.1016/S0168-8278(00)80131-2
  81. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med 1967;67:337-348 https://doi.org/10.7326/0003-4819-67-2-337
  82. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503 https://doi.org/10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
  83. Freeny PC. Portal vein tumor thrombus: demonstration by computed tomographic ateriography. J Comput Assist Tomogr 1980;4:263-264 https://doi.org/10.1097/00004728-198004000-00030
  84. Stevens WR, Johnson CD, Stephens DH, Batts KP. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. Radiology 1994;191:531-537 https://doi.org/10.1148/radiology.191.2.8153335
  85. Shin WY, Suh KS, Lee HW, Kim J, Kim T, Yi NJ, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010;16:678-684 https://doi.org/10.1002/lt.22047
  86. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753-758 https://doi.org/10.1016/j.jamcollsurg.2003.07.003
  87. Llovet JM, Fuster J, Bruix J; Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10(2 Suppl 1):S115-S120 https://doi.org/10.1002/lt.20034
  88. Suh YJ, Kim MJ, Choi JY, Park MS, Kim KW. Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging. Liver Transpl 2012;18:1171-1178 https://doi.org/10.1002/lt.23502
  89. Miyata R, Tanimoto A, Wakabayashi G, Shimazu M, Nakatsuka S, Mukai M, et al. Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography. J Gastroenterol 2006;41:987-995 https://doi.org/10.1007/s00535-006-1890-2
  90. Nishie A, Yoshimitsu K, Asayama Y, Irie H, Tajima T, Hirakawa M, et al. Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. AJR Am J Roentgenol 2008;190:81-87 https://doi.org/10.2214/AJR.07.2810
  91. Ariizumi S, Kitagawa K, Kotera Y, Takahashi Y, Katagiri S, Kuwatsuru R, et al. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOBDTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2011;18:575-585 https://doi.org/10.1007/s00534-010-0369-y
  92. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056-2066 https://doi.org/10.1007/s00330-011-2165-8
  93. Tsuda N, Harada K, Matsui O. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. J Gastroenterol Hepatol 2011;26:568-576 https://doi.org/10.1111/j.1440-1746.2010.06494.x
  94. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004;40:212-218 https://doi.org/10.1016/j.jhep.2003.10.008
  95. Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC on hepatobiliary phase images of gadoxetic acidenhanced MRI: correlation with clinical and pathological features. Eur J Radiol 2012;81:3877-3882 https://doi.org/10.1016/j.ejrad.2012.07.021
  96. Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009;193:1053-1060 https://doi.org/10.2214/AJR.08.1946
  97. Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010;255:824-833 https://doi.org/10.1148/radiol.10091557
  98. Asayama Y, Tajima T, Nishie A, Ishigami K, Kakihara D, Nakayama T, et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol 2011;80:e243-e248 https://doi.org/10.1016/j.ejrad.2010.10.032
  99. Kim HY, Choi JY, Kim CW, Bae SH, Yoon SK, Lee YJ, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis. Liver Transpl 2012;18:850-857 https://doi.org/10.1002/lt.23426
  100. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44:793-798 https://doi.org/10.1007/s00535-009-0056-4
  101. Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 2011;197:W44-W52 https://doi.org/10.2214/AJR.10.5845
  102. Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 2012;265:780-789 https://doi.org/10.1148/radiol.12120226
  103. Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology 2010;256:817-826 https://doi.org/10.1148/radiol.10092214
  104. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013;267:776-786 https://doi.org/10.1148/radiol.13120775
  105. Vasuri F, Golfieri R, Fiorentino M, Capizzi E, Renzulli M, Pinna AD, et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011;459:141-146 https://doi.org/10.1007/s00428-011-1099-5
  106. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989;64:1700-1707 https://doi.org/10.1002/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z
  107. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994;73:2464-2471 https://doi.org/10.1002/1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9
  108. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81 https://doi.org/10.1074/mcp.M300094-MCP200
  109. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138-151 https://doi.org/10.1111/j.1365-2559.2006.02468.x
  110. Jeong HT, Kim MJ, Kim YE, Park YN, Choi GH, Choi JS. MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int 2012;32:430-440
  111. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461 https://doi.org/10.1158/0008-5472.CAN-07-6013
  112. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-1024 https://doi.org/10.1053/j.gastro.2008.12.004
  113. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556 https://doi.org/10.1053/j.gastro.2007.04.025
  114. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416 https://doi.org/10.1038/nm1377
  115. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-857 https://doi.org/10.1111/j.1349-7006.2003.tb01366.x
  116. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996;149:1167-1175
  117. Fan ST. Selection of HCC patients for liver transplantation: the Milan criteria, Hangzhou criteria and beyond. Hepatobiliary Pancreat Dis Int 2008;7:233-234
  118. Choi JY, Kim MJ, Park YN, Lee JM, Yoo SK, Rha SY, et al. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. AJR Am J Roentgenol 2011;197:399-405 https://doi.org/10.2214/AJR.10.5439
  119. Maier SE, Sun Y, Mulkern RV. Diffusion imaging of brain tumors. NMR Biomed 2010;23:849-864 https://doi.org/10.1002/nbm.1544
  120. White NS, Dale AM. Distinct effects of nuclear volume fraction and cell diameter on high b-value diffusion MRI contrast in tumors. Magn Reson Med 2014;72:1435-1443 https://doi.org/10.1002/mrm.25039
  121. Sykova E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev 2008;88:1277-1340 https://doi.org/10.1152/physrev.00027.2007
  122. Pfeuffer J, Flogel U, Dreher W, Leibfritz D. Restricted diffusion and exchange of intracellular water: theoretical modelling and diffusion time dependence of 1H NMR measurements on perfused glial cells. NMR Biomed 1998;11:19-31 https://doi.org/10.1002/(SICI)1099-1492(199802)11:1<19::AID-NBM499>3.0.CO;2-O
  123. Le Bihan D. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed 1995;8:375-386 https://doi.org/10.1002/nbm.1940080711
  124. Kim YK, Kim CS, Han YM, Lee YH. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol 2011;66:489-496 https://doi.org/10.1016/j.crad.2010.09.007
  125. Xu PJ, Yan FH, Wang JH, Lin J, Ji Y. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging 2009;29:341-349 https://doi.org/10.1002/jmri.21650
  126. Vandecaveye V, De Keyzer F, Verslype C, Op de Beeck K, Komuta M, Topal B, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009;19:2456-2466 https://doi.org/10.1007/s00330-009-1431-5
  127. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264:761-770 https://doi.org/10.1148/radiol.12112517
  128. Yu JS, Chung JJ, Kim JH, Cho ES, Kim DJ, Ahn JH, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging 2011;29:985-992 https://doi.org/10.1016/j.mri.2011.04.010
  129. An C, Park MS, Jeon HM, Kim YE, Chung WS, Chung YE, et al. Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI. Eur Radiol 2012;22:1701-1708 https://doi.org/10.1007/s00330-012-2421-6
  130. Heo SH, Jeong YY, Shin SS, Kim JW, Lim HS, Lee JH, et al. Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor. Korean J Radiol 2010;11:295-303 https://doi.org/10.3348/kjr.2010.11.3.295
  131. Muhi A, Ichikawa T, Motosugi U, Sano K, Matsuda M, Kitamura T, et al. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 2009;30:1005-1011 https://doi.org/10.1002/jmri.21931
  132. Nakanishi M, Chuma M, Hige S, Omatsu T, Yokoo H, Nakanishi K, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 2012;19:1302-1309 https://doi.org/10.1245/s10434-011-2066-8
  133. Nishie A, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, et al. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol 2011;80:e29-e33 https://doi.org/10.1016/j.ejrad.2010.06.019
  134. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009;193:438-444 https://doi.org/10.2214/AJR.08.1424
  135. Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014;20:3059-3068 https://doi.org/10.3748/wjg.v20.i12.3059
  136. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:708-710 https://doi.org/10.2214/ajr.181.3.1810708
  137. Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 2008;27:834-839 https://doi.org/10.1002/jmri.21316
  138. Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience. Radiology 2006;239:448-456 https://doi.org/10.1148/radiol.2392042202
  139. Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, Claussen CD, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009;193:W301-W307 https://doi.org/10.2214/AJR.08.2289
  140. Yuan Z, Ye XD, Dong S, Xu LC, Xu XY, Liu SY, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 2010;75:e9-e14
  141. Kele PG, van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol 2010;16:1567-1576 https://doi.org/10.3748/wjg.v16.i13.1567

피인용 문헌

  1. Curative Resection of Single Primary Hepatic Malignancy: Liver Imaging Reporting and Data System Category LR-M Portends a Worse Prognosis vol.209, pp.3, 2015, https://doi.org/10.2214/ajr.16.17478
  2. Small hepatocellular carcinomas displayed as a ring enhancing mass on arterial phase MRI in the chronically diseased liver vol.72, pp.11, 2017, https://doi.org/10.1016/j.crad.2017.07.001
  3. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study vol.286, pp.3, 2015, https://doi.org/10.1148/radiol.2017162846
  4. Value of Image Subtraction for the Identification of Hepatocellular Carcinoma Capsule on Gadoxetic Acid-Enhanced MRI vol.79, pp.6, 2018, https://doi.org/10.3348/jksr.2018.79.6.340
  5. CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners vol.6, pp.2, 2018, https://doi.org/10.14218/jcth.2017.00062
  6. The capsule appearance of hepatocellular carcinoma in gadoxetic acid-enhanced MR imaging : Correlation with pathology and dynamic CT vol.97, pp.25, 2015, https://doi.org/10.1097/md.0000000000011142
  7. Radiomics and radiogenomics of primary liver cancers vol.25, pp.1, 2015, https://doi.org/10.3350/cmh.2018.1007
  8. Bleeding Liver Masses: Imaging Features With Pathologic Correlation and Impact on Management vol.213, pp.1, 2019, https://doi.org/10.2214/ajr.19.21240
  9. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS vol.44, pp.9, 2019, https://doi.org/10.1007/s00261-019-02077-1
  10. IVIM improves preoperative assessment of microvascular invasion in HCC vol.29, pp.10, 2015, https://doi.org/10.1007/s00330-019-06088-w
  11. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) vol.9, pp.6, 2015, https://doi.org/10.1159/000509424
  12. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy vol.10, pp.None, 2015, https://doi.org/10.3389/fonc.2020.600233
  13. Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation vol.37, pp.1, 2015, https://doi.org/10.1080/02656736.2020.1825837
  14. Expression of Organic Anion Transporting Polypeptides in an H-Ras 12V Transgenic Mouse Model of Spontaneous Hepatocellular Carcinoma vol.62, pp.7, 2015, https://doi.org/10.3349/ymj.2021.62.7.622
  15. Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation vol.76, pp.2, 2015, https://doi.org/10.1016/j.crad.2020.09.011
  16. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm vol.31, pp.7, 2021, https://doi.org/10.1007/s00330-020-07601-2
  17. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma vol.54, pp.7, 2015, https://doi.org/10.1111/apt.16563